Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Haubrich

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
Future Microbiology|September 4, 2024
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 yearStefan Esser, Alexy Inciarte, Itzchak Levy, et al.
Plos Pathogens|February 6, 2014
Loss of circulating CD4 T cells with B cell helper function during chronic HIV infectionKristin L Boswell, Robert Paris, Eli Boritz, et al.
HIV Medicine|December 27, 2023
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohortsStefan Esser, Jason Brunetta, Alexy Inciarte, et al.
The Journal of Infectious Diseases|September 22, 2017
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials ParticipantsKatie R Mollan, Camlin Tierney, Jacklyn N Hellwege, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
Antiviral Therapy|October 1, 2004
Clinically validated genotype analysis: guiding principles and statistical concernsFrançoise Brun-Vézinet, Dominique Costagliola, Mounir Ait Khaled, et al.
HIV Clinical Trials|December 20, 2011
Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious DiseasesDavid W Haas, Daniel R Kuritzkes, Marylyn D Ritchie, et al.
The Journal of Infectious Diseases|February 6, 2008
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitroKersten K Koelsch, Lin Liu, Richard Haubrich, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
The New England Journal of Medicine|May 16, 2008
Class-sparing regimens for initial treatment of HIV-1 infectionSharon A Riddler, Richard Haubrich, A Gregory DiRienzo, et al.
Future Microbiology|September 4, 2024
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 yearStefan Esser, Alexy Inciarte, Itzchak Levy, et al.
Plos Pathogens|February 6, 2014
Loss of circulating CD4 T cells with B cell helper function during chronic HIV infectionKristin L Boswell, Robert Paris, Eli Boritz, et al.
HIV Medicine|December 27, 2023
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohortsStefan Esser, Jason Brunetta, Alexy Inciarte, et al.
The Journal of Infectious Diseases|September 22, 2017
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials ParticipantsKatie R Mollan, Camlin Tierney, Jacklyn N Hellwege, et al.
Antiviral Therapy|October 2, 2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adultsJacob P Lalezari, Edwin DeJesus, Donald W Northfelt, et al.
Infectious Diseases Now|July 16, 2023
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19Nadir Arber, Pallav L Shah, Lambert Assoumou, et al.
Antiviral Therapy|October 1, 2004
Clinically validated genotype analysis: guiding principles and statistical concernsFrançoise Brun-Vézinet, Dominique Costagliola, Mounir Ait Khaled, et al.
HIV Clinical Trials|December 20, 2011
Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious DiseasesDavid W Haas, Daniel R Kuritzkes, Marylyn D Ritchie, et al.
The Journal of Infectious Diseases|February 6, 2008
Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitroKersten K Koelsch, Lin Liu, Richard Haubrich, et al.
Pageof 11